AbbVie announced Rinvoq (upadacitinib 15 mg and 30 mg, once daily) plus topical corticosteroids (TCS) met the co-primary endpoints and all secondary endpoints in AD Up, the third… read more.
Orion’s phase III REFALS trial evaluating the efficacy of oral Simdax (levosimendan) in treatment of amyotrophic lateral sclerosis (ALS) patients did not reach its pre-specified endpoints. Orion has… read more.
Pfizer Inc. and BioNTech SE announced the start of a global (except for China) Phase II/III safety and efficacy clinical study to evaluate a single nucleoside-modified messenger RNA… read more.
Health Canada has approved, with conditions, remdesivir (Velkury) from Gilead Sciences to treat COVID-19 patients. Remdesivir is used to treat those with pneumonia who need extra oxygen to… read more.
MC2 Therapeutics, announced that the FDA has approved Wynzora Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) for once-daily topical treatment of plaque psoriasis in adults 18 years of… read more.
Article written by Bruce Sylvester Symptoms of opioid withdrawal increase the odds that a drug-injecting person will share needles or have a non-fatal overdose..
scPharmaceuticals Inc. announced that the FDA has accepted for review the company’s New Drug Application (NDA) resubmission for Furoscix. scPharmaceuticals is developing Furoscix a proprietary, subcutaneously delivered furosemide… read more.
Imfinzi (durvalumab) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC) in combination… read more.
Article written by Bruce Sylvester Glycated hemoglobin A1c (HbA1c) greater than 7% correlates with an increased risk of cardiovascular events in elderly patients..
The Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product Ayvakyt (avapritinib), from Blueprint… read more.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Calquence (acalabrutinib), from AstraZeneca,… read more.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Zynrelef (bupivacaine and meloxicam),… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
